Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
Public ClinicalTrials.gov record NCT02418754. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy. The secondary objectives of the study were the following: * To explore the effect of 2 dose levels of IVT REGN2176-3 on anatomical changes of CNV in participants with nAMD compared to IAI monotherapy (at week 12) * To evaluate if short-term treatment with REGN2176-3 followed by IAI monotherapy offered the same or additional benefit compared to continuous treatment with REGN2176-3. Also to determine if there was benefit in initiating IAI treatment prior to REGN2176-3 compared to continuous treatment with IAI. * To assess the safety and tolerability of IVT REGN2176-3 in participants with nAMD
Study identification
- NCT ID
- NCT02418754
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 505 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2015 (Actual)
- Primary completion
- Aug 17, 2016 (Actual)
- Completion
- Apr 3, 2017 (Actual)
- Last update posted
- Oct 26, 2020
2015 – 2017
United States locations
- U.S. sites
- 75
- U.S. states
- 32
- U.S. cities
- 75
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Arcadia | California | — | — |
| Not listed | Beverly Hills | California | — | — |
| Not listed | Irvine | California | — | — |
| Not listed | Mountain View | California | — | — |
| Not listed | Oceanside | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Santa Ana | California | — | — |
| Not listed | Colorado Springs | Colorado | — | — |
| Not listed | Fort Lauderdale | Florida | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Melbourne | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Winter Haven | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Marietta | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Oak Forest | Illinois | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Urbana | Illinois | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Shawnee Mission | Kansas | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Paducah | Kentucky | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Towson | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Jackson | Michigan | — | — |
| Not listed | Southfield | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Florissant | Missouri | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Bloomfield | New Jersey | — | — |
| Not listed | New Brunswick | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | East Setauket | New York | — | — |
| Not listed | Great Neck | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Orchard Park | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Asheville | North Carolina | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Kingston | Pennsylvania | — | — |
| Not listed | Monroeville | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Florence | South Carolina | — | — |
| Not listed | Ladson | South Carolina | — | — |
| Not listed | West Columbia | South Carolina | — | — |
| Not listed | Rapid City | South Dakota | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Abilene | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | McAllen | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | The Woodlands | Texas | — | — |
| Not listed | Willow Park | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Burlington | Vermont | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Bellevue | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02418754, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2020 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02418754 live on ClinicalTrials.gov.